Table 1.
Baseline characteristics of the included human studies
| Author, Publication year | Study type | Number of patients | Age | Duration of infertility (years) | Previous IVF cycles | Number of administration | Administered volume per ovary (ml) |
|---|---|---|---|---|---|---|---|
| Garavelas A et al., 2023 [36] | prospective observational study | 253 | 43.73 ± 5.89a | N.A | N.A | 1 | 4 |
| Najafian A et al., 2023 [37] | prospective observational study | 50 | 39 (35–43)b | 4 (2–6)b | N.A | 1 | 4 |
| Safarova S et al., 2023 [38] | Retrospective observational | 60 | 36.5 ± 0.8a | 3.8 ± 2.6a | N.A | 1—3 | 0.6 |
| Tanha FD et al., 2023 [39] | prospective observational study | 20 | 41.8 ± 1.82a | 9.7 ± 1.89a | N.A | 1 | 3 |
| Tickoo S et al., 2023 [40] | Retrospective observational | 66 | N.A | N. A | N.A | 3 | 2 |
| Keikha F et al., 2022 [33] | prospective observational study | 12 | 40.04 ± 3.91a | 2.79 ± 1.79a | 0.50 ± 0.67a | 1 | 4 |
| Barad DH et al., 2022 [41] | prospective observational study | 80 | 44.17 ± 5.45a | N.A | ≥ 1 | 1 | 1.5 |
| Cakiroglu Y. et al., 2022 [42] | prospective observational study | 496 | 40.3 ± 4a | 7.4 ± 6a | N.A | 1 | 3.5 |
| Hosseinisadat R et al., 2022 [43] | prospective observational study | 22 | 33.91 ± 6.58a | 4.3 ± 4.25a | N.A | 1 | N.A |
| Rezk MR et al., 2022 [44] | prospective observational study | 50 | 31.1 ± 4.38a | 2.66 ± 1.33a | > 1 | 1 | 1 |
| Navali N et al., 2022 [45] | prospective observational study | 35 | 40.43 ± 0.26c | N.A | ≥ 1 | 1 | 2 |
| Parvanov D et al., 2022 [46] | prospective observational study | 66 | 40.5 (34–46)d | N.A | 2.9 (2–5)d | 2 | 0.5 |
| Tülek F et al., 2022 [47] | Retrospective observational | 69 | 38.04 ± 3.86a | N.A | N.A | 1 | 2 |
| Aflatoonian A et al., 2021 [48] | prospective observational study | 26 | 34.88 ± 4.5a | 5.06 ± 1.91a | N.A | 2 | 1.5 than 3 |
| Dubinskaya ED et al., 2021 [49] | prospective observational study | 52 | 37.68 ± 7.26a | 5.07 ± 2.3a | 2.78 ± 1.15a | 1 | 1 |
| Farimani M et al., 2021 [50] | Retrospective observational | 72 | N.A | N.A | N.A | 1 | 2 |
| Hsu C et al., 2021 [51] | prospective observational study | 12 | 44.42 ± 2.84a | 13 ± 7.7a | N.A | 1 | 3 |
| Pacu I et al., 2021 [52] | retrospective observational study | 20 | 37.4 (31–44)d | N.A | > 1 | 1 | 2–4 |
| Cakiroglu Y et al., 2020 [53] | prospective observational study | 311 | 34.8 ± 4.3a | 6.8 ± 4.9a | N.A | 1 | 4–8 |
| Melo P et al., 2020 [54] | prospective observational study | 46 | 41(39–44)b | N.A | N.A | 3 | 0.2 |
| Petryk N and Petryk M, 2020 [55] | prospective observational study | 38 | 31-45e | N.A | > 2 | 1 | 0.7 |
| Sfakianoudis K et al., 2020 [22] | prospective observational study | 119 | 41.66 ± 5.66a | N.A | N.A | 1 | 4 |
| Sills ES et al., 2020 [56] | prospective observational study | 182 | 45.4 ± 6a | ≥ 1 | ≥ 1 | 1 | ≥ 1 |
| Abdullah TH et al., 2019 [57] | prospective observational study | 50 | 39.74 ± 7.03a | 5.2 ± 3.82a | N.A | 1 | 1.25 |
| Farimani M et al., 2019 [58] | prospective observational study | 12 | 35.57 ± 3.8a | 6.5 ± 3.77a | 4 ± 0.94a | 1 | 2 |
| Tremellen K et al., 2022 [59] | Case series | 18 | 40 (35–42)b | 3 (3–4)b | 5.05 ± 2.09a | 1 | 3 |
| Pantos K et al., 2019 [60] | Case series | 3 | 37.67 ± 7.93a | N.A | N.A | 1 | 4 |
| Sfakianoudis K et al., 2019 [6] | Case series | 3 | 38.0 ± 1.41a | N.A | 12 ± 4.97a | 1 | 5 |
| Sills ES et al., 2018 [61] | Case series | 4 | 42.0 ± 4.0a | 5 ± 2.08a | ≥ 1 | 1 | 1 |
| Shrivastava J et al., 2024 [62] | Case report | 1 | 29 | 1.5 | 1 | 1 | 1.5–2 |
| Kulakova EV et al., 2022 [63] | Case report | 1 | 34 | 5 | 4 | 2 | 1.5 |
| Kraevaya EE et al., 2021 [64] | Case report | 1 | 31 | 2 | 1 | 1 | 0.5 |
| Merhi Z et al., 2021 [65] | Case report | 1 | 33 | > 1 | 0 | 1 | 3 |
| Sabouni R et al., 2021 [66] | Case report | 1 | 35 | 5 | 0 | 1 | 0.5 |
| El Sherbeny MF, 2020 [67] | Case report | 1 | 34 | 3 | 2 | 1 | 5 |
| Hsu C et al., 2020 [68] | Case report | 1 | 37 | 4 | 2 | 1 | 2.5 |
| Sills ES et al., 2020 [69] | Case report | 1 | 41 | N.A | 10 | 1 | ≥ 1 |
| Sfakianoudis K et al., 2018 [70] | Case report | 1 | 40 | 6 | 0 | 1 | 4 |
N.A. Not available, or inappropriate reporting
aMean and Standard deviation
bMedian and Interquartile range
cMean and Standard error
dMean and Minimum – Maximum
eMinimum and Maximum